Literature DB >> 6166416

Solid-phase radioimmunoassay for detection of alcoholic hyalin antigen (AHAg) and antibody (anti-AH).

A Kehl, A Schober, U Junge, K Winckler.   

Abstract

Alcoholic hyalin (AH) was isolated and purified from post-mortem livers of patients with alcoholic hepatitis. Antibodies against AH (anti-AH) were raised in guinea-pigs. Their specificity was demonstrated by immunofluorescence and by immunoabsorption. The antisera were positive in immunofluorescence and complement fixation up to serum dilutions of 1:320 and 1:32 respectively. In order to achieve a higher sensitivity a solid-phase radioimmunoassay (SP-RIA) was established for detection of alcoholic hyalin antigen (AHAg) and anti-AH. Anti-AH could thus be measured up to a 10(5) serum dilution. Using a blocking test, solubilized AH at protein concentrations as low as 80 to 160 ng/ml could be detected. With this SP-RIA, neither AHAg nor anti-AH was found in the sera of 32 patients with histologically proven alcoholic hepatitis. The sera were likewise negative by indirect immunofluorescence, complement fixation and immune adherence haemagglutination test.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6166416      PMCID: PMC1537143     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  14 in total

Review 1.  Immunologic reactivity and alcoholic liver disease.

Authors:  R K Zetterman; C M Leevy
Journal:  Bull N Y Acad Med       Date:  1975-04

2.  Preparation of iodine-131 labelled human growth hormone of high specific activity.

Authors:  W M HUNTER; F C GREENWOOD
Journal:  Nature       Date:  1962-05-05       Impact factor: 49.962

3.  Immunological aspects of alcoholic hepatitis.

Authors:  U Junge; A Kehl; A Schober; K Winckler
Journal:  Gastroenterology       Date:  1978-07       Impact factor: 22.682

4.  Morphologic variants of alcoholic hyalin.

Authors:  H Yokoo; O T Minick; F Batti; G Kent
Journal:  Am J Pathol       Date:  1972-10       Impact factor: 4.307

5.  A method of isolation of Mallory bodies in a purified fraction.

Authors:  S W French; T J Ihrig; M L Norum
Journal:  Lab Invest       Date:  1972-03       Impact factor: 5.662

6.  The ultrastructure of Mallory body filaments.

Authors:  K D Wiggers; S W French; B A French; B N Carr
Journal:  Lab Invest       Date:  1973-12       Impact factor: 5.662

7.  Hepatocellar hyalin (Mallory bodies) in long term griseofulvin-treated mice: a new experimental model for the study of hyalin formation.

Authors:  H Denk; F Gschnait; K Wolff
Journal:  Lab Invest       Date:  1975-06       Impact factor: 5.662

8.  Mallory bodies compared with microfilament hyperplasia.

Authors:  J S Sim; K E Franks; S W French; M G Caldwell
Journal:  Arch Pathol Lab Med       Date:  1977-08       Impact factor: 5.534

9.  Formation and involution of Mallory bodies ("alcoholic hyalin") in murine and human liver revealed by immunofluorescence microscopy with antibodies to prekeratin.

Authors:  H Denk; W W Franke; R Eckerstorfer; E Schmid; D Kerjaschki
Journal:  Proc Natl Acad Sci U S A       Date:  1979-08       Impact factor: 11.205

10.  Alcoholic hyalin antigen (AHAg) and antibody (AHAb) in alcoholic hepatitis.

Authors:  N Kanagasundaram; S Kakumu; T Chen; C M Leevy
Journal:  Gastroenterology       Date:  1977-12       Impact factor: 22.682

View more
  3 in total

1.  Isolation of Mallory bodies and an attempt to demonstrate cell mediated immunity to Mallory body isolate in patients with alcoholic liver disease.

Authors:  C Gluud; F Hardt; J Aldershvile; P Christoffersen; H Lyon; J Nielsen
Journal:  J Clin Pathol       Date:  1981-09       Impact factor: 3.411

2.  Circulating immune complexes and complement concentrations in patients with alcoholic liver disease.

Authors:  C Gluud; H Jans
Journal:  J Clin Pathol       Date:  1982-04       Impact factor: 3.411

Review 3.  Alcohol induced liver disease.

Authors:  K A Fleming; J O McGee
Journal:  J Clin Pathol       Date:  1984-07       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.